A's Aroon Indicator triggered a bullish signal on November 06, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 209 similar instances where the Aroon Indicator showed a similar pattern. In 141 of the 209 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 67%.
Following a +4.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where A advanced for three days, in 187 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The 10-day RSI Indicator for A moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 19 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 68 cases where A's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 65%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on A as a result. In 56 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.
The Moving Average Convergence Divergence Histogram (MACD) for A turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 25 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 57%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where A declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
A broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 11 (best 1 - 100 worst), indicating outstanding price growth. A’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.692) is normal, around the industry mean (67.298). P/E Ratio (34.334) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (1.447) is also within normal values, averaging (3.473). Dividend Yield (0.006) settles around the average of (0.002) among similar stocks. P/S Ratio (5.910) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 45 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. A’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.
The Moving Average Convergence Divergence (MACD) for APYX turned positive on October 12, 2026. Looking at past instances where APYX's MACD turned positive, the stock continued to rise in 41 of 45 cases over the following month. The odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on APYX as a result. In 90 of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
APYX moved above its 50-day moving average on November 05, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for APYX crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
Following a +7.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where APYX advanced for three days, in 196 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The 10-day RSI Indicator for APYX moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 22 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 57 of 59 cases where APYX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where APYX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
APYX broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for APYX entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.575) is normal, around the industry mean (4.142). P/E Ratio (-14.650) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.390) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.196) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. APYX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APYX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
A | APYX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 79 | 32 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | 19 Undervalued | |
PROFIT vs RISK RATING 1..100 | 67 | 100 | |
SMR RATING 1..100 | 45 | 99 | |
PRICE GROWTH RATING 1..100 | 11 | 59 | |
P/E GROWTH RATING 1..100 | 44 | 15 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
APYX's Valuation (19) in the Medical Specialties industry is in the same range as A (24) in the Biotechnology industry. This means that APYX’s stock grew similarly to A’s over the last 12 months.
A's Profit vs Risk Rating (67) in the Biotechnology industry is somewhat better than the same rating for APYX (100) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than APYX’s over the last 12 months.
A's SMR Rating (45) in the Biotechnology industry is somewhat better than the same rating for APYX (99) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than APYX’s over the last 12 months.
A's Price Growth Rating (11) in the Biotechnology industry is somewhat better than the same rating for APYX (59) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than APYX’s over the last 12 months.
APYX's P/E Growth Rating (15) in the Medical Specialties industry is in the same range as A (44) in the Biotechnology industry. This means that APYX’s stock grew similarly to A’s over the last 12 months.
| A | APYX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 68% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 65% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 65% | 1 day ago 85% |
| MACD ODDS (%) | 1 day ago 57% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 62% | 1 day ago 83% |
| TrendMonth ODDS (%) | 1 day ago 63% | 1 day ago 86% |
| Advances ODDS (%) | 3 days ago 62% | 14 days ago 84% |
| Declines ODDS (%) | 1 day ago 63% | 20 days ago 89% |
| BollingerBands ODDS (%) | 1 day ago 67% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 67% | 1 day ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 2 FA rating(s) are green while APYX’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 2 TA indicator(s) are bullish while APYX’s TA Score has 5 bullish TA indicator(s).
A (@Medical Specialties) experienced а -0.12% price change this week, while APYX (@Medical/Nursing Services) price change was +12.69% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -4.83%. For the same industry, the average monthly price growth was -5.05%, and the average quarterly price growth was +38.36%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.89%. For the same industry, the average monthly price growth was -4.69%, and the average quarterly price growth was -1.76%.
A is expected to report earnings on Nov 23, 2026.
APYX is expected to report earnings on Mar 18, 2027.
Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (-2.89% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
A.I.dvisor indicates that over the last year, A has been closely correlated with TMO. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if A jumps, then TMO could also see price increases.
A.I.dvisor tells us that APYX and SGHT have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that APYX and SGHT's prices will move in lockstep.
| Ticker / NAME | Correlation To APYX | 1D Price Change % | ||
|---|---|---|---|---|
| APYX | 100% | +2.39% | ||
| SGHT - APYX | 28% Poorly correlated | +1.58% | ||
| ITOC - APYX | 26% Poorly correlated | +8.46% | ||
| CLPT - APYX | 25% Poorly correlated | +4.56% | ||
| EMBC - APYX | 25% Poorly correlated | +1.56% | ||
| A - APYX | 25% Poorly correlated | -0.52% | ||
More | ||||